PremiumThe FlyCosciens Biopharma announces possible delay in filing 2024-end documents COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides PremiumCompany AnnouncementsCOSCIENS Biopharma Restructures Board After Resignation Cosciens Biopharma director Carolyn Egbert resigns COSCIENS Biopharma Welcomes New Board Director PremiumThe FlyCosciens Biopharma says primary efficacy endpoint of DETECT-trial not met COSCIENS Biopharma Inc (USA) trading resumes COSCIENS Biopharma Inc (USA) trading halted, volatility trading pause